Crossmark

Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?

Crossref DOI link: https://doi.org/10.1186/s13023-022-02236-6

Published Online: 2022-02-16

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bruscolini, Alice

Marenco, Marco

Albanese, Giuseppe Maria

Lambiase, Alessandro http://orcid.org/0000-0002-8974-991X
Sacchetti, Marta
License Information

Text and Data Mining valid from 2022-02-16

Version of Record valid from 2022-02-16
More Information

Article History

Received: 17 May 2021

Accepted: 6 February 2022

First Online: 16 February 2022

Declarations

:

: This study was approved by the Investigational Review Board (IRB) of University Sapienza of Rome, Italy (IRB number 5338) with informed consent obtained at follow-up visits.

: Images are entirely unidentifiable and there are no details on individuals reported within the manuscript.

: AL, MS, and AB are paid consultants for Dompé Farmaceutici SpA, Milan, Italy. GMA and MM have no conflicts of interest to disclose.

Document is current

Any future updates will be listed below